Letter to the Editor concerning ‘cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’

• A. L. Stevenson,
• S. Chang-Douglass,
• P. Kazmierska,
• A. Benedict,
• K. Azimpour,
• P. Dorling

Affiliations

A. L. Stevenson

Health Economics and Outcomes Research, Global Rare Diseases, Chiesi Ltd, Manchester, UK

S. Chang-Douglass

Modeling & Simulation, Evidence Synthesis, Modeling and Communication, Evidera Ltd, London, UK

P. Kazmierska

Modeling & Simulation, Evidence Synthesis, Modeling and Communication, Evidera Ltd, London, UK

A. Benedict

Scientific Affairs, Modeling & Simulation, Evidence Synthesis, Modeling and Communication, Evidera Ltd, Budapest, Hungary

K. Azimpour

Health Economics and Outcome Research, Chiesi Canada Corp, Montreal, Canada

P. Dorling

Head of Health Economics Outcome Research & Real World Evidence, Rare Diseases, Chiesi USA, Inc, Boston, MA, USA